ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

VRCI Verici Dx Plc

8.00
0.00 (0.00%)
28 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Verici Dx Plc LSE:VRCI London Ordinary Share GB00BM8HZD43 ORD GBP0.001
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 8.00 7.50 8.50 8.00 8.00 8.00 8,147 07:34:14
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Business Services, Nec 0 -11.41M -0.0670 -1.79 20.44M

Verici Dx PLC Verici Dx announces new research initiative

31/01/2024 7:00am

RNS Non-Regulatory


RNS Number : 4040B
Verici Dx PLC
31 January 2024
 

Verici Dx plc

("Verici Dx" or the "Company") 

 

Verici Dx announces new research initiative

Collaboration with leading Australian researchers as part of Government genomics programme

 

Verici Dx (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces an exciting collaboration with The Westmead Institute for Medical Research based in Sydney, Australia, on a newly awarded, 4-year federal research grant. This forms part of the Australian Government's Medical Research Future Fund (MRFF) "Genomics Health Futures Mission".

 

Through the Genomics Health Futures Mission, the Australian Government is investing A$500 million in genomic medicine research with the objective to save or transform the lives of more than 200,000 Australians through genomic research to deliver better testing, diagnosis, and treatment, including in the field of organ transplants.

 

The collaboration between Verici Dx and The Westmead Institute for Medical Research aims to improve the understanding of factors contributing to graft loss in organ transplants, focusing on genetic differences between donor and recipient beyond the well-known HLA1 mismatches. By incorporating a broader range of genetic data through multiple cohorts with varying ethnic backgrounds, the goal is to enhance the prediction and management of risks associated with organ transplants, ultimately leading to better outcomes for patients. Verici Dx will use its CAP/CLIA-certified laboratory to perform sequencing from blood samples across 3 sites, as well as apply its existing biomarker tests to the samples to assess their use in this diverse population.

 

In addition to the research, the programme also involves a health economics analysis, an important step for new assays (tests) to be officially recognised and approved for use in Australia.

 

Dr. Philip O'Connell, Executive Director of The Westmead Institute for Medical Research and Professor Faculty of Medicine and Health, said: "We aim to inform new guidelines for kidney transplant management in Australia and educate the next generation of nephrologists on the emerging role of genetics and genomics for the delivery of personalised medicine in kidney transplantation."

 

Patti Connolly, Chief Operating Officer at Verici Dx, added: "We are excited that through this partnership, our team has the opportunity to collaborate with world-leading researchers in transplant and genomic science. Through this joint effort we aim to contribute to significant advancements in biomarker development and for Verici Dx to expand its reach in Australia."

 

1     Human leukocyte antigens

 

Enquiries:

 

Verici Dx

www.vericidx.com

Sara Barrington, CEO 

investors@vericidx.com

Julian Baines, Chairman

 

 

 



Singer Capital Markets (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / Sam Butcher / Jalini Kalaravy

 

 




 

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

 

About The Westmead Institute for Medical Research

 

The Westmead Institute for Medical Research (WIMR) is a multidisciplinary research institute with more than 300 research scientists grouped into 11 research groups. It is renown of its research in cancer, immunology, liver disease, renal disease and transplantation. WIMR researchers are using genomics and genetic data to develop new ways of treating ovarian cancer, liver cancer, autoimmune diseases such as Sjogren's syndrome and SLE, genetic causes of kidney failure as well as developing predictive biomarkers for risk stratification in kidney transplantation. The Westmead Health Precinct serves a large multi-ethnic Australian community. It is is the largest centre for clinical trials in Australia and WIMR has strong links with the Oncology, Renal and Transplant Units at Westmead Hospital.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABXGDBDDXDGSG

1 Year Verici Dx Chart

1 Year Verici Dx Chart

1 Month Verici Dx Chart

1 Month Verici Dx Chart

Your Recent History

Delayed Upgrade Clock